N | Overall survival | ||||
---|---|---|---|---|---|
Univariable analysis | Multivariable analysis | ||||
HR (95% CI) | P | HR (95% CI) | P | ||
All | 305 | ||||
Age (years) | 0.588 | ||||
<60 | 106 | Ref | |||
≥60 | 199 | 0.929 (0.711-1.213) | |||
Sex | 0.916 | ||||
Male | 158 | Ref | |||
Female | 147 | 1.007 (0.888-1.142) | |||
T stage | < 0.001 | < 0.001 | |||
T1-2 | 227 | Ref | Ref | ||
T3 | 78 | 1.744 (1.333-2.361) | 2.065 (1.542-2.767) | ||
N stage | < 0.001 | < 0.001 | |||
N0-1 | 262 | Ref | Ref | ||
N2 | 43 | 2.487 (1.754-3.526) | 3.049 (2.127-4.373) | ||
AJCC stage | < 0.001 | < 0.001 | |||
I-II | 262 | Ref | Ref | ||
III | 43 | 2.487 (1.754-3.526) | 3.049 (2.127-4.373) | ||
Grade | 0.001 | < 0.001 | |||
Well and moderate differentiation | 191 | Ref | Ref | ||
Low differentiation | 114 | 1.536 (1.187-1.989) | 1.632 (1.255-2.124) | ||
Intratumoral PD-L2 | < 0.001 | < 0.001 | |||
Low expression | 238 | Ref | Ref | ||
High expression | 67 | 1.858 (1.387-2.487) | 1.892 (1.402-2.552) | ||
Intratumoral CD3 | 0.07 | 0.003 | |||
Low cell densities | 220 | Ref | Ref | ||
High cell densities | 85 | 0.768 (0.577-1.022) | 0.646 (0.482-0.865) | ||
Stromal CD3 | 0.053 | 0.041 | |||
Low cell densities | 119 | Ref | Ref | ||
High cell densities | 186 | 1.295 (0.997-1.683) | 1.319 (1.012-1.721) | ||
Intratumoral CD8 | 0.143 | ||||
Low cell densities | 260 | Ref | |||
High cell densities | 45 | 1.292 (0.917-1.821) | |||
Stromal CD8 | 0.066 | 0.372 | |||
Low cell densities | 272 | Ref | Ref | ||
High cell densities | 33 | 0.663 (0.427-1.028) | 0.814 (0.517-1.279) | ||
Intratumoral FOXP3 | 0.006 | 0.002 | |||
Low cell densities | 257 | Ref | Ref | ||
High cell densities | 48 | 1.580 (1.138-2.193) | 1.704 (1.215-2.389) | ||
Stromal FOXP3 | 0.008 | 0.132 | |||
Low cell densities | 292 | Ref | Ref | ||
High cell densities | 13 | 2.157 (1.227-3.790) | 1.647 (0.860-3.153) | ||
Risk score | < 0.001 | < 0.001 | |||
Low score | 228 | Ref | Ref | ||
High score | 77 | 2.047 (1.549-2.706) | 1.836 (1.379-2.444) |